Overall survival of non-small cell lung cancer who treated with systemic therapy: The experience at a regional hospital, Bandar Lampung

Abstract

Background: The benchmark for the success of cancer treatment is the survival rate. Although the hope for survival is increasing, there are still concerns regarding the cost of treating lung cancer with targeted therapy which is very expensive and has not yet been included in the national formulary for third generation EGFR-TKI target therapy (osimertinib).

Method: Analytic descriptive with retrospective cohort design processed with SPSS 25 with log rank test and shown with Kaplan Meier product limit curve. Data was taken at Dr.Hi.Abdul Moeloek Hospital from January 2020 to December 2022 during the Covid 19 pandemic.

Results: Group of Lung adenocarcinoma treated by EGFR-TKI 39 subjects. The lung adenocarcinoma group was treated with paclitaxel-carboplatin 53 subjects.The median survival time of the group treated with EGFR-TKI was 7 (95% CI: 3.805-10.195) months, while the group receiving paclitaxel carboplatin was 5 months (95% CI: 3.788- while the overall median survival was 6 months (95% CI: 4.836- 7.164) there is no significant difference with the p value: 0.209.

Conclusion: The median survival rate of two groups at 6 months was not significantly different.